Saturday July 22nd 2017

Teva asks Supreme Court to review Copaxone ruling

Teva Pharmaceuticals has filed a petition with the U.S. Supreme Court asking for a review of a lower court’s ruling that invalidated key patents for the company’s multiple sclerosis drug Copaxone. A Teva spokeswoman confirmed the filing, but said the company would have no additional comment on the matter. Copaxone, which generated about $3.8 billion in sales for Teva (NYSE: TEVA) last year, is scheduled to lose patent protect in May. Based in Israel, Teva has its North American headquarters… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)

See the original article here: 

Teva asks Supreme Court to review Copaxone ruling

Leave a Comment

More from category

Mothers who breastfeed might have lower multiple sclerosis risk
Mothers who breastfeed might have lower multiple sclerosis risk

(Reuters Health) - Women who breastfeed may have a lower risk of developing multiple sclerosis later in life compared [Read More]

Lipoic acid in nutritional supplements found to help prevent multiple sclerosis, study finds
Lipoic acid in nutritional supplements found to help prevent multiple sclerosis, study finds

(Natural News) The results of a new pilot study showed the efficacy of lipoic acid in the reduction of whole brain [Read More]

Multiple sclerosis symptoms: Immune system problems can trigger PARALYSIS of the legs
Multiple sclerosis symptoms: Immune system problems can trigger PARALYSIS of the legs

MULTIPLE sclerosis - commonly abbreviated to MS - is a type of autoimmune disease which can cause problems with vision, [Read More]

National Patient-Advocacy Organizations Oppose ACA Repeal
National Patient-Advocacy Organizations Oppose ACA Repeal

/About-the-Society/News/National-Patient-Advocacy-Organizations-Oppose-ACA [Read More]

Exclusive: Nurses reluctant to discuss disability with MS patients
Exclusive: Nurses reluctant to discuss disability with MS patients

Nearly two-thirds of specialist nurses are reluctant to discuss disability with patients who have multiple sclerosis, [Read More]